Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Use of such pills, which include Sanofi SA's Ambien and other similar drugs, was significantly higher for those in their 50s as well as age 80 and older, according to the findings from the Centers for Disease Control and Prevention. Overall about 8.6 million people, or 4 percent of U.S. adults reported recently using sleep medication, CDC's National Center for Health Statistics said in a report. But data showed higher use among middle-aged adults ages 50 to 59 and the elderly. Six percent of those ages 50 to 59 said they had taken a prescription sleep pill in the last 30 days, and 7 percent of those age 80 and older reported such use. In between, the numbers dip slightly below 6 percent for those in their 60s and 70s. In comparison, just 2 percent of those aged 20-39 said they had recently taken a sleep aid. CDC researcher Yinong Chong said people in their 50s could have trouble sleeping because of work and family stress. "It gives the picture of a sandwiched group who has family, not only children but also probably elderly parents but still you're likely to be in the workforce, so you get squeezed at both ends in terms of family responsibility and job responsibility," she said. Sleep may improve when people retire before potential chronic health problems kick in and begin interfering with sleep, Chong said, adding more study is needed. The data also showed that 5 percent of women surveyed said they had recently taken a sleep aid compared to about 3 percent of male respondents, according to CDC's report. Chong said it was not clear why women were more likely to use the drugs. While previous data have tracked prescriptions dispensed for sleep aids, the CDC said its study is the first based on a survey of actual use of such drugs. Researchers for the Atlanta-based health agency's National Center for Health Statistics questioned a sampling of adults age 20 and older about whether they had used prescription sleep aids within the last 30 days and asked participants to show interviewers the prescription medication. "You get how many people are actually using them," Chong said in an interview, noting that prescription data could include multiple prescriptions for one patient or prescriptions that are never filled or even used. "This is actual use." Prescription sleep aids have become somewhat controversial because their effect can linger even after some patients wake up. The U.S. Food and Drug Administration has begun taking a closer look at sleep drugs, ordering lower-doses for Ambien and similar pills amid concerns that their active ingredient remained in patients' blood the following morning at levels high enough to make driving and other activities dangerous. And just last month, the FDA rejected an experimental sleep drug from Merck & Co Inc, saying the proposed doses were not safe but that a lower-dose version might be acceptable. Not surprisingly, respondents to CDC's study who said they slept five hours or less each night or those diagnosed with a sleep disorder were more likely to report using prescription aids. Additionally, more whites and people with higher levels of education also reported greater use, the agency said. Socioeconomic factors are likely behind those numbers, Chong said, since patients must be able to afford a doctor's care and the medication. According to prescription data from IMS Health, Ambien and other versions of the drug zolpidem was ranked 15th among the most dispensed medications in the United States.

Output: Use of sleeping pills highest among older Americans: CDC.

Input: Consider Input: Both warnings are true. On September 18, 2006, the U.S. Food and Drug Administration expanded its warning about spinach, telling consumers not to eat any raw spinach, not just pre-packaged spinach as had initially been announced. The FDA also announced that it's probe into the sources of spinach contaminated with a strain of E.coli bacterium had been expanded to other companies. On September 15, 2006, the FDA had announced that Natural Selection Foods of San Juan Bautista, California was recalling all of its products that contain spinach that have "best if used by" dates of August 17, 2006 through October 1, 2006 The FDA is continuing to investigate whether any other brands are involved. According to an FDA release, "Natural Selection Foods, LLC brands include: Natural Selection Foods, Pride of San Juan, Earthbound Farm, Bellissima, Dole, Rave Spinach, Emeril, Sysco, O Organic, Fresh Point, River Ranch, Superior, Nature's Basket, Pro-Mark, Compliments, Trader Joe's, Ready Pac, Jansal Valley, Cheney Brothers, Coastline, D'Arrigo Brothers, Green Harvest, Mann, Mills Family Farm, Pro*Act, Premium Fresh, Snoboy, The Farmer's Market, Tanimura & Antle, President's Choice, Cross Valley, and Riverside Farms. These products include spinach and any salad with spinach in a blend, both retail and food service products. Products that do not contain spinach are not part of this recall." The FDA said that 109 cases of illness had been reported to the Centers for Disease Control including one death and 14 cases of what is called Hemolytic Uremic Syndrome (HUS), a form of kidney failure. States included in the warning include: California, Connecticut, Idaho, Indiana, Kentucky, Maine, Michigan, Minnesota, Nevada, New Mexico, New York, Ohio, Oregon, Pennsylvania, Tennessee, Utah, Virginia, Washington, Wisconsin, and Wyoming. The FDA said the affected products were also distributed to Canada and Mexico. The other story was focused on Minneapolis, Minnesota. The Dateline show aired in April, 2006. When more than 10 cases of sick people with similar symptoms showed up within three days in September, 2005, a public health investigation was launched. The Minnesota Department of Public Health speculated that the sicknesses were food-related. One of the investigators suspected E.coli because of the symptoms of abdominal cramps and severe, bloody diarrhea. The problem was that E.coli poisoning was more commonly associated with eating contaminated and improperly cooked meat. One of the foods that most of the sick people had eaten was salads made from bagged lettuce. When a public health warning was issued about the salads, one of the victims called investigators from his hospital room and said he still had a partially-eaten bag in his refrigerator. That lettuce was tested and became the first evidence that the E.coli had come from the pre-packaged salads. The odd thing was that the bacterium was found in the lettuce, not just on it. As a result of that 2005 outbreak, the Dole company issued a voluntary recall for the "American Blend" and "Classic Romaine" packaged salads. The U.S. Food and Drug Administration also issued a nationwide health alert in October, 2005, about the particular Dole salads implicated in the outbreak. According to Dateline, 26 people from three states got ill, some of them seriously. There were no known deaths and there have not been any repeats of the problem. Updated 9/18/06 Comments

Output: There are a couple of stories about this. One warning says that a documentary on Dateline TV showed that E.coli bacteria were found in pre-packaged bags of salad and that the Dole company has issued a recall on some bags. The other from September of 2006 says the Food and Drug Administration has issued an alert that a strain of E.coli bacterium has been found in several U.S. states and that pre-packaged bags of spinach are suspect.

Input: Consider Input: The story mentioned that apixabane would cost more than warafarin, and included a quote from a company spokesperson to indicate that the exact price is uncertain as the medication has not yet been approved. The story also presented a reasoned examination of total costs for the use of warafin that accounted not just for per pill costs but also the expenses associated with the routine blood draws to examine warafarin levels. The story provided the absolute decrease in the number of strokes or clots, major bleeding events and hemorrhagic stroke as compared to the people in the study taking warafarin. The story provided good insight about possible problems associated with apixabane in patients with coronary artery disease who were simultaneously taking two blood thinners in addition to apixabane. The story provided a clear explanation about the nature of the patients, the size of the study, and the fact that it was a randomized clinical trial. The story did not engage in overt disease mongering. The story quoted a study researcher, a company spokesperson, and a cardiologist who did not appear to have ties to the study reported on. The story compared the outcome measure of apixabane to warafarin; in addition, it indicated that there is another medication in the same category that has been recently approved by the FDA. The story was clear that apixabane, the medication reported on, was experimental. The story was clear that there is already a similar type of drug that has recently been approved for use by the FDA. While the story referenced a news release, it does not appear to be its sole source of information.
Output: New Blood Thinner May Outperform Warfarin for Irregular Heartbeat